Skip to main content
Exosens logo

Exosens — Investor Relations & Filings

Ticker · EXENS ISIN · FR001400Q9V2 LEI · 969500R3AKTPEDO9EG76 PA Manufacturing
Open in API
Filings indexed 101 across all filing types
Latest filing 2025-03-03 Earnings Release
Country FR France
Listing PA EXENS

About Exosens

http://www.exosens.com

Exosens is a high-tech company specializing in the innovation, development, and manufacture of high-end electro-optical technologies for amplification, detection, and imaging. The company provides mission-critical components and solutions for demanding environments. Its product portfolio covers a wide optical spectrum from ultraviolet (UV) to longwave infrared (LWIR) and includes image intensifier tubes, advanced digital and infrared cameras, and hyperspectral imaging systems. Exosens also produces a comprehensive range of detectors for electrons, ions, photons, X-rays, neutrons, and gamma radiation, as well as nuclear instrumentation and microwave amplifiers. These technologies serve key markets such as defense and surveillance, life sciences, industrial control, and nuclear safety.

Recent filings

Filing Released Lang Actions
Exosens enregistre des résultats 2024 très solides, supérieurs aux prévisions de l'introduction en bourse ; Dynamique de croissance soutenue attendue pour 2025-2026
Earnings Release Classification · 100% confidence The document is a detailed announcement titled "EXOSENS ENREGISTRE DES RÉSULTATS 2024 TRÈS SOLIDES, SUPÉRIEURS AUX PRÉVISIONS DE L'INTRODUCTION EN BOURSE..." and contains key financial highlights (revenue, EBITDA, net income) for the fiscal year ended December 31, 2024. It includes comparative tables with 2023 figures, management commentary, segment performance breakdowns, and forward-looking guidance for 2025 and 2024-2026. The content is comprehensive, covering the full annual performance, which strongly indicates an Annual Report or a detailed Earnings Release. Since it provides extensive financial tables and detailed segment analysis, it goes beyond a simple 'Earnings Release' (ER) which usually contains only key highlights. However, it is not explicitly labeled as a '10-K' (which is the US SEC term for the official yearly report). Given the context of a comprehensive report detailing the full year's results, including the balance sheet context (leverage ratio, net debt) and detailed segment performance, it aligns best with the comprehensive nature of an Annual Report, even if it might be a local market equivalent or a detailed press release accompanying the statutory filing. Since '10-K' is specifically defined as the 'Official yearly report covering company activity and full financial performance,' and this document serves that function by presenting the full 2024 results, '10-K' is the most appropriate classification for a comprehensive annual financial disclosure, assuming this is the primary annual filing document. FY 2024
2025-03-03 French
Exosens delivers very strong full-year 2024 results, overperforming on its IPO guidance; Sustained growth dynamic anticipated for 2025-2026
Earnings Release Classification · 100% confidence The document explicitly states, 'Exosens today publishes its results for the fiscal year ended 31 December 2024.' It contains detailed financial tables (Revenue, Adjusted EBITDA, Net profit, Balance Sheet metrics) covering the full fiscal year (FY 2024) and compares them to the previous year (FY 2023). The length (over 34,000 characters) confirms it is a comprehensive report, not just a brief announcement. This content structure is characteristic of a full Annual Report, which in the US context is filed as a 10-K. Since the definitions provided do not have a specific 'Annual Report' code distinct from 10-K, and this document serves the function of a full annual financial disclosure, 10-K is the most appropriate classification for a comprehensive yearly report, even if the company is European (many global databases map comprehensive annual reports to 10-K structure for consistency). If a specific 'Annual Report' code existed for non-US filers, that might be considered, but based on the provided list, 10-K fits the description of 'Official yearly report covering company activity and full financial performance.' FY 2024
2025-03-03 English
Photonis Launches Two Market-Leading Solutions
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 3612U' and concludes with information about 'Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This strongly indicates the document is a regulatory news service announcement, which is a general press release or regulatory update. The content describes the launch of new products (Cricket™ Pro and PhotonPix™) by Photonis (a brand of Exosens). Since this is a product announcement/press release distributed via RNS and does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA), the most appropriate classification is the general regulatory announcement/press release category, RNS.
2025-01-23 English
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du Code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. This type of filing specifically reports changes in significant share ownership, where an investor or concert group crosses ownership thresholds (like 5%, 10%, 15%, etc.). The text explicitly states that a concert group crossed the 50% threshold downwards, now holding 45.84% of capital and voting rights. This directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (1811 chars), but it is a primary regulatory disclosure, not an announcement of another report.
2025-01-20 French
Bilan semestriel du contrat de liquidité d'Exosens avec Kepler Cheuvreux
Transaction in Own Shares Classification · 98% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ D'EXOSENS AVEC KEPLER CHEUVREUX" (Semi-annual report of the liquidity contract of Exosens with Kepler Cheuvreux). It details the activity (purchases and sales of shares) under a liquidity contract for the period July 18, 2024, to December 31, 2024. This type of report, detailing transactions related to share buybacks or stabilization activities, directly corresponds to the definition of 'Transaction in Own Shares' (POS). Although it is a periodic report, the specific nature of the activity (liquidity contract management) makes POS a more precise fit than a general regulatory filing (RNS) or a capital change announcement (SHA).
2025-01-14 French
Half-yearly report on Exosens' liquidity contract with Kepler Cheuvreux
Regulatory Filings Classification · 95% confidence The document is a 'Half-Yearly Report on Exosens' Liquidity Contract', which details the transactions and resources held under a liquidity contract with Kepler Cheuvreux. This type of disclosure is a standard regulatory requirement for companies listed on French exchanges to report on market-making activities. It does not represent a financial report of the company's performance (10-K or IR) but rather a specific regulatory disclosure regarding share liquidity. Therefore, it falls under the 'Regulatory Filings' category. H2 2024
2025-01-14 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.